Market Intelligence, Clinical Progress, and High-Purity Reagents for PDZ Scaffold Inhibition & Targeted Protein Degradation
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GIPC1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | GIPC1 PDZ Domain Protein (115-333 aa) – High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. | View GIPC1 Products |
| Gene Delivery | GIPC1 Promise-ORF / Lentivirus – Full-length ORF for stable cell lines. Codon-optimized for mammalian expression. Titers >1×10⁸ TU/mL. | View GIPC1 Products |
| Gene Silencing | GIPC1 siRNA Set (3 unique sequences) – For knockdown verification and specificity controls. KD efficiency >80% at mRNA level. | View GIPC1 Products |
| Benchmark Ab | Anti-GIPC1 (Research Grade) – Recombinant positive control for western blot/IHC. | View GIPC1 Products |
| Paralog Control | GIPC2 PDZ Domain Protein – Critical for selectivity assays (off-target counter-screening). | View GIPC2 Products |
| Paralog Control | GIPC3 PDZ Domain Protein – Homology comparison for PPI inhibitor selectivity. | View GIPC3 Products |
| Binding Partner | IGF1R ECD-Fc Fusion Protein – Co-receptor for GIPC1-mediated trafficking studies. | View IGF1R Products |
| Related Target | NRP1 – Critical transmembrane co-receptor interacting with GIPC1. | View NRP1 Products |
| Related Target | MYO6 – Motor protein linking GIPC1 to intracellular vesicular transport. | View MYO6 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| PDZ Domain Selectivity (GIPC1 vs GIPC2/3) | Human/Mouse/Cyno ortholog proteins available with >95% purity; mass spectrometry verified sequence identity; homolog panel for cross-reactivity. |
| PPI Inhibitor Screening (Small molecule/Peptide) | High-purity PDZ domain (>95%) with native folding confirmed by circular dichroism; suitable for FP/SPR/BLI assays. |
| PROTAC Degradation Validation | Full-length GIPC1 Lentivirus for stable cell line construction; HEK293T packaged, titers >1×10⁸ TU/mL; validated siRNA for rescue experiments. |
| Lack of Cellular Controls | Validated siRNA included for specificity checks (KD efficiency >80% at mRNA level); validated lentiviral expression vectors for stable cell lines. |
| Cross-species Translation | Human, Mouse, and Cynomolgus monkey GIPC1 proteins with verified binding affinities in orthogonal assays. |
| Target Validation Ambiguity | Strictly sequence-verified proteins; theoretical MW and mass spec quality control; antibody controls for western blot/IHC. |
Live GIPC1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of GIPC1 (also known as Synectin) represents a paradigm shift from traditional extracellular receptor targeting to intracellular scaffold disruption. As a PDZ domain-containing protein critical for receptor trafficking (IGF1R, VEGFR1, Neuropilin-1), GIPC1 overexpression correlates with chemoresistance in pancreatic, breast, and colorectal cancers. Historically considered "undruggable" due to its intracellular nature, the global R&D landscape is shifting focus from generalized chemotherapy to targeted small molecule and peptide inhibitors designed to disrupt the GIPC1 PDZ domain interactions. The current R&D landscape is transitioning from academic target validation to drug discovery, with major emphasis on Protein-Protein Interaction (PPI) inhibitors, PROTAC-mediated degradation, and combination strategies with anti-angiogenic agents.
"The race for GIPC1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to intracellular PPI inhibitors and targeted degradation. As first-generation small molecules enter preclinical optimization, the next wave of R&D is targeting PDZ domain specificity and paralog selectivity (GIPC1 vs. GIPC2/GIPC3) to minimize compensatory resistance mechanisms."
Competitive Modality & Indication Snapshot
Connect market trends to assay needs.
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| PPI Inhibitors (Small Molecule & Peptide) | Academic consortia, Emerging Biotech, Academic Spin-offs | Pancreatic Cancer, Breast Cancer, Solid Tumors (Angiogenesis) | PDZ Domain Binding Assay (Need high-purity GIPC1 PDZ with native structure) and PPI Disruption Assay (need native-folded domain constructs) |
| PROTACs | Degrader-focused Biotechs, Early Discovery R&D | Solid Tumors (IGF1R resistant), Refractory Solid Tumors | Cell-based Degradation Assay (Need GIPC1 Lentivirus for stable cell lines) and Ternary Complex Validation (Need strictly sequence-verified proteins) |
| siRNA / RNAi | Oncology RNAi platforms, Emerging RNA Companies | Pancreatic, Colorectal, Ovarian Cancer | Knockdown Validation (Need validated siRNA sets with specificity controls, standardized siRNA and Ab controls) |
| Bi-functional Degraders (Molecular Glue) | Molecular glue developers | Hematological Malignancies | Target Engagement Assay (Need full-length GIPC1 protein) |
Related Targets Strategy
Based on signaling pathways and compensatory mechanisms, the following targets are recommended for cross-sell: GIPC2/GIPC3 (paralogs essential for selectivity panels), IGF1R (direct binding partner for trafficking studies), NRP1 (co-receptor for angiogenesis), MYO6 (motor protein for vesicular transport), VEGFR1, Neuropilin-1, and RGS19 (GAIP). These proteins form a comprehensive network for GIPC1 PPI and degradation assays.